Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.51 |
| ▸ | CETP | P11597 | 10/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922046 | 0.88 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRCETPGPBAR1 | |
| SCHEMBL16501914 | 0.87 | KDM4E (0.43) | PTGDR2TBXA2RPTGDRCETPGPBAR1 | |
| SCHEMBL1922343 | 0.86 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDRCETPGPBAR1 | |
| SCHEMBL1922015 | 0.84 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDRCETPGPBAR1 | |
| SCHEMBL1923684 | 0.80 | PTGDR2 (0.46) | PTGDR2TBXA2RPTGDRCETPGPBAR1 | |
| SCHEMBL1922459 | 0.79 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1922294 | 0.79 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL3151897 | 0.79 | DGAT2 (0.45) | PTGDR2CETPGPBAR1 | |
| SCHEMBL1922522 | 0.79 | PTGDR2 (0.60) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1923803 | 0.78 | GPBAR1 (0.51) | PTGDR2TBXA2RPTGDRCETPGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8049015-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2328869-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010037054-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.